Zocor UK ad
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson MSD has amended a print advertisement for ZocorHeart-Pro (simvastatin 10 mg) that contained the phrase "protection of hearts" and had not been submitted to the MHRA for "pre-vetting," the Medicines & Healthcare products Regulatory Agency announces Oct. 29. The UK health agency cited the ad because the phrase "fails to convey to the reader that Zocor Heart-Pro does not provide absolute protection from risk of heart attack and that it should [be] taken in conjunction with lifestyle changes." J&J MSD said the "error had resulted from a failure in [the firm's] internal procedures over the holiday period" and ensured the problem "would not happen again"...
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.